Puma Biotechnology (NASDAQ:PBYI) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Puma Biotechnology (NASDAQ:PBYI) released its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02, Zacks reports. Puma Biotechnology had a return on equity of 36.17% and a net margin of 17.45%.The business had revenue of $75.50 million for the quarter, compared to the consensus estimate of $68.60 million.

Here are the key takeaways from Puma Biotechnology’s conference call:

• Q4 2025 results showed continued commercial momentum with total revenue of $75.5M and product net revenue of $59.9M, and management guides full‑year 2026 net NERLYNX product revenue of $194M–$198M and GAAP net income of $10M–$13M.
• Management expects higher gross‑to‑net reductions (FY2026 ~27.5%–28.5%; Q1 ~29.5%–30.5%) and is guiding a Q1 2026 net loss of $8M–$10M, which could pressure near‑term margins and results.
• Clinical programs advanced — the ALISCA‑Breast1 trial reached and exceeded its 150‑patient target ahead of schedule (164 enrolled) with interim data expected in Q2 2026, and ALISCA‑Lung1 is escalating doses (60mg, planned 70mg) with an interim readout also expected in Q2 2026, representing potential near‑term catalysts.
• Commercial demand trends were healthy with ex‑factory bottle sales up ~12% q/q to 3,298 bottles, SD (specialty distributor) channel growth strong (SD +17% q/q, +46% y/y), and recent international launches (Algeria, Thailand) expanding reach.
• Puma expects R&D to rise ~30%–35% and SG&A to rise 3%–5% in 2026; cash and securities were ~$97.5M at year‑end with outstanding debt ≈$22M, so higher spend could strain liquidity if commercial trends weaken.

Puma Biotechnology Stock Performance

Shares of PBYI opened at $7.60 on Friday. Puma Biotechnology has a fifty-two week low of $2.58 and a fifty-two week high of $7.68. The firm has a 50-day simple moving average of $6.49 and a 200-day simple moving average of $5.58. The company has a market capitalization of $382.96 million, a price-to-earnings ratio of 10.27 and a beta of 1.22.

Insider Activity at Puma Biotechnology

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 18,012 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $5.88, for a total transaction of $105,910.56. Following the completion of the sale, the chief executive officer directly owned 7,145,951 shares of the company’s stock, valued at $42,018,191.88. This represents a 0.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Douglas M. Hunt sold 5,014 shares of Puma Biotechnology stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total value of $29,482.32. Following the completion of the transaction, the insider owned 155,907 shares in the company, valued at $916,733.16. This trade represents a 3.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 43,937 shares of company stock valued at $257,513. 23.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Puma Biotechnology

A number of large investors have recently bought and sold shares of the stock. Barclays PLC increased its holdings in shares of Puma Biotechnology by 1.9% in the 4th quarter. Barclays PLC now owns 81,434 shares of the biopharmaceutical company’s stock valued at $485,000 after acquiring an additional 1,553 shares during the last quarter. Cerity Partners LLC increased its position in Puma Biotechnology by 18.2% in the fourth quarter. Cerity Partners LLC now owns 12,072 shares of the biopharmaceutical company’s stock worth $72,000 after buying an additional 1,862 shares during the period. BNP Paribas Financial Markets lifted its stake in Puma Biotechnology by 39.7% in the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 2,290 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Puma Biotechnology by 2.5% during the fourth quarter. First Trust Advisors LP now owns 122,800 shares of the biopharmaceutical company’s stock valued at $731,000 after acquiring an additional 3,021 shares during the period. Finally, Royal Bank of Canada grew its position in shares of Puma Biotechnology by 3.8% during the first quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company’s stock worth $254,000 after acquiring an additional 3,117 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on PBYI. Wall Street Zen lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Puma Biotechnology in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.